Clinically, the presence of CD36-positive cells has been correlated with a lower survival rate in many carcinomas, including breast cancer, and inhibition of CD36 impairs metastasis in breast cancer-derived tumours, turning this receptor into an important biomarker of tumour cell dissemination and a potential new target to reduce cell invasion. This evidence concerns the gene CD36 and breast carcinoma.